Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York98
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT06270498RecruitingPhase 4
Oral iron for heart failure: exercise and quality of life study
This study tests whether an oral iron supplement (a pill called sucrosomial iron) can help people with heart failure who have low iron feel better, have more energy, and walk farther. Participants will take the iron pill or a placebo (a pill without the active ingredient) for a period and will do exercise tests and answer questionnaires to see how they improve.
Pisa, TuscanyAges 18 years+ - NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+ - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+ - NCT06261333Enrolling by invitation
Quality of life study for HHT patients
This study looks at how hereditary hemorrhagic telangiectasia (HHT) affects your day-to-day life and well-being. By joining, you'll answer questions to help doctors better understand the impact of the condition.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT06270888RecruitingPhase 1
Shorter radiation treatment for multiple myeloma
This trial tests a shorter course of radiation therapy for up to 5 bone lesions that have come back or not responded to treatment. It aims to see if this approach is safe and helps control the disease.
Chicago, IllinoisAges 18 years+ - NCT06257394RecruitingPhase 2
Treating high-risk childhood leukemia in Korea
This trial tests a new treatment plan for children with very high-risk acute lymphoblastic leukemia. It aims to improve outcomes for patients whose leukemia has specific genetic markers or has not responded well to initial treatment.
DaeguAges 1–19 - NCT06263491RecruitingPhase 2
Pirtobrutinib and Rituximab for Low/Medium Risk MCL
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
Houston, TexasAges 18 years+ - NCT06259292Recruiting
HHT patient registry tracking long-term outcomes
This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.
Birmingham, AlabamaAges Any age - NCT06265584RecruitingPhase 2
Using ATG to prevent graft-versus-host disease after stem cell transplant
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
Birmingham, AlabamaAges 18–75 - NCT06260891RecruitingPhase 2
Zinc study for sickle cell disease and bone health
This study tests if taking zinc supplements can improve bone health in people with sickle cell disease. It's for those with certain types of sickle cell disease (SS or S-Beta zero thalassemia) who are not on chronic transfusions or zinc supplements.
Oakland, CaliforniaAges 15–40 - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06261060RecruitingPhase 2
Sirolimus to improve blood cell production in RUNX1 familial platelet disorder
This trial tests a low dose of sirolimus, a medicine that may help your bone marrow make more blood cells, especially platelets. It is for people with a specific genetic change (RUNX1) that affects blood cell production.
Houston, TexasAges 18 years+ - NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Fountain Valley, CaliforniaAges 1 day–17 years - NCT06237803Recruiting
Blood sample collection for plasma cell disorders
This study is collecting blood samples from people with plasma cell disorders to help researchers learn more about these conditions. It may be a good fit if you haven't started treatment yet and are willing to donate samples.
MelbourneAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Birmingham, AlabamaAges 1–18 - NCT06235229RecruitingPhase 1/Phase 2
GC012F for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
BeijingAges 18–75 - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Phoenix, ArizonaAges 50–92 - NCT06234904RecruitingPhase 1
IBR733 cell therapy for acute myeloid leukemia
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Suzhou, JiangsuAges 18–74 - NCT04745195Recruiting
Study of complement activity in microangiopathy affecting kidneys
This study looks at signs of a clotting problem in tiny blood vessels (called TMA) that can affect kidney function. The goal is to better understand the role of the body’s complement system and how it relates to different causes of this illness.
Maastricht, LimburgAges 18 years+ - NCT06241729Recruiting
Observation of first-time DLBCL treatment at Charleroi hospital
This study is watching how people with newly diagnosed diffuse large B cell lymphoma (a blood cancer) are treated for the first time at Grand Hôpital de Charleroi. It collects information to help doctors learn more about the disease and its care.
Charleroi, HainautAges 18 years+ - NCT06247189Recruiting
ICOPE program for older adults with myeloma
This trial tests whether a program called ICOPE MONITOR, which uses a smartphone app or chatbot, can help older adults with multiple myeloma stay healthier and manage their care. It may be a good fit if you are 70+ and starting your first or second treatment.
ToulouseAges 70 years+ - NCT06240754RecruitingPhase 2
Study of enasidenib for low blood counts with IDH2 mutation
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
St Louis, MissouriAges 18 years+ - NCT06240715Recruiting
Umbilical cord milking for premature babies who need help at birth
This study tests whether gently squeezing the umbilical cord before clamping it (called cord milking) helps premature babies who are not vigorous at birth. It is being done in hospitals with fewer resources to find safe and effective ways to improve oxygen and blood flow right after delivery.
Belagavi, KarnatakaAges birth–10 minutes
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,384 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.